The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
Abstract
Dabigatran is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. It has shown antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action and predictable pharmacodynamic response. Peak plasma concentrations of dabigatran occur 1 to 2 hours after ingestion of the prodrug. The terminal half-life of dabigatran is 12 to 14 hours in elderly volunteers. Dabigatran is not metabolized by cytochrome P450 isoenzymes and does not interact with food. Dabigatran has a low potential for drug-drug interactions and is predominantly renally excreted. Dabigatran etexilate as chronic therapy effectively prevents the recurrence of venous thromboembolism and cardioembolic stroke. For the first time, it has been demonstrated clinically that there may be an effective and safe alternative to warfarin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Cited by
Wen, H., Jung, H., & Li, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9814-9 · Cited by 574
Prodrugs—from Serendipity to Rational Design
Huttunen, K. M., Raunio, H., & Rautio, J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003459 · Cited by 505
New insights into the mechanisms of venous thrombosis
Mackman, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60229 · Cited by 436
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Dabigatran Etexilate: A New Oral Thrombin Inhibitor
Hankey, G. J., & Eikelboom, J. W. (2011) · Circulation · doi:10.1161/circulationaha.110.004424 · Cited by 348
Metadata
- Authors
- Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2010-10
- Volume
- 30
- Issue
- 10
- Pages
- 1885-1889
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2170251955
- Cited by
- 216
- References
- 1
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. https://app.cochat.ai/papers/10.1161/atvbaha.110.203604
- The paper
- Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010). Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.110.203604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.